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Crown ethers, first described by Pedersen et al.1 are 
macrocyclic polyethers well known for their noncovalent ion 
binding properties. Their common names include the number and 
type of atoms in the polyether ring. The ring size of these 
molecules controls their binding selectivity for a range of metal 
ions, thus 18-crown-6 has high affinity for potassium while 15-
crown-5 selects sodium cations. To explain this, a high complex 
stability has been associated with greater penetration of the metal 
cation into the polyether cavity. 
Crown ether macrocycles are known in all ring sizes from 9 to 
at least 60, leading to great variety in structures (exceeding 10000 
examples).2 Therefore, crown ethers have been extensively 
studied from different aspects, including sensor applications, 
biological model systems (for example, abiotic ion channels)3 
and biological functionality, especially for anticancer and 
antimicrobial effects.2,4,5 Crown ether derivatives function 
similarly to natural ionophores (such as gramicidin) and have 
thus been used to study several biological processes, in particular 
due to their channel forming and ion transport capabilities 
through lipid membranes.5 Despite, large macrocylic compounds 
do not comply with the druglike, “rule-of-five” properties,6 the 
potential of macrocycles for drug discovery has attracted 










Figure 1. Structure of the crown ether acyl derivatives. 
 






A set of crown ethyl acyl derivatives based on 18-crown-6 moiety was synthesized and 
evaluated for biological activity. In vitro antiproliferative profiling demonstrated significant 
activities against HBL-100, HeLa, SW1573 and WiDr human cell lines. The most active 
compound exhibited GI50 values in the range of 3.7-5.6 µM. Antimicrobial evaluation showed 
that three polyaromatic compounds were active against Staphylococcus aureus (MIC90 values 
from 8.3 µM to 50 µM), whereas a (decyloxy)benzene substitution exhibited moderate activity 
against Candida albicans (MIC90 values 36 µM). According to SAR evaluation, the size of the 
crown ether and the acyl side chain had a significant effect on the bioactivity. Aromatic moieties 
close to the acyl group led to improved bioactivity as exemplified by some of the tested 
compounds. These results provide further evidence on the potential of crown ethyl structure as a 
scaffold for developing new biological probes and lead candidates for drug development. 
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Table 1. Antiproliferative activity (GI50) against human solid tumour and non-tumour cellsa 
 




1a >100 >100 >100 >100  -0.96 
1b >100 >100 >100 >100  0.86 
1c 72.0 (± 13.0) 71.0 (± 9.3) 51.0 (± 6.0) 33.0 (± 0.8)  3.27 
2c >100 >100 >100 >100  3.46 
3c >100 >100 >100 >100  3.66 
1d 69.0 (± 23.0) 52.0 (± 3.4) >100 >100  2.04 
1e 64.0 (± 24.0) 79.0 (± 25.0) 78.0 (± 5.4) >100  2.56 
1f >100 >100 >100 >100  1.46 
1g 20.0 (± 6.2) 41.0 (± 28.0) 24.0 (± 2.5) 66.0 (± 12.0) 24 (± 4.0) 4.63 
1h >100 >100 >100 >100  1.50 
1i >100 >100 >100 >100  -0.59 
1j 57.0 (± 2.1) 48.0 (± 7.6) 48.0 (± 5.9) >100  1.20 
1k 50.0 (± 2.6) 56.0 (± 4.5) 54.0 (± 3.2) 56.0 (± 4.5) >100 1.12 
1l 6.4 (± 0.4) 7.8 (± 6.5) 4.4 (± 0.7) 6.2 (± 3.8) 8.2 (± 0.1) 3.51 
1m 40.0 (± 3.4) 63.0 (± 7.3) 54.0 (± 3.2) 56.0 (± 4.5) >100 2.40 
1n 29.0 (± 2.6) 35.0 (± 2.2) 36.0 (± 2.9) 24.0 (± 6.5) 22 (± 9.6) 2.34 
1o 21.0 (± 1.0) 17.0 (± 0.4) 18.0 (± 4.4) 19.0 (± 1.4) 19 (± 1.5) 3.94 
1p 5.0 (± 0.9) 3.7 (± 0.7) 3.8 (± 0.1) 5.6 (± 1.3) 5.4 (± 2.4) 3.10 
1q 11.0 (± 0.6) 12.0 (± 1.3) 8.8 (± 1.0) 12.0 (± 1.4) 18 (± 3.8) 2.51 
CDDP 1.9 (± 0.2) 2.0 (± 0.3) 3.0 (± 0.4) 26.0 (± 5.3)   
VP-16 1.4 (± 0.1) 3.3 (± 1.6) 15.0 (± 1.5) 23.0 (± 3.1)   
a Values are given in µM and are means of two to three experiments; standard deviation is given in parentheses. 
b cLogP values were calculated using the Schrodinger small-molecule drug discover suite conditions. 
 
Herein we report the synthesis of a series of crown ether acyl 
derivatives and the evaluation of their antimicrobial and 
antiproliferative properties. The antimicrobial activity was tested 
against Gram (+) and Gram (-) bacteria as well as against the 
model yeast Candida albicans. Previous reports describe 
dialkyldiaza-18-crown-6 ethers as inhibitors of bacterial 
growth.8,9 In addition, the antiproliferative profile was evaluated 
in vitro against a panel of human solid tumour cell lines. Thus we 
first synthetized compounds 1c, 2c and 3c where the same 
cyclohexyl side-chain was attached to 18-6, 15-5 and 12-4 crown 
ether moieties. Based on their antiproliferative activity (Table 1) 
we selected 18-crown-6 derivatives for further development, 
changing the length of the side chain and the size of the attached 
cyclic moiety.  
 
Table 2. Antimicrobial primary screening of compounds. Ciprofloxacin and amphotericin B were used as positive controls. Data is 
presented as average inhibition% (±standard deviation, n = 3) at 50 µM concentration. Inhibition results >90% are in bold 
Compound C. albicans ATCC 90028 E. faecalis ATCC 29212 S. aureus ATCC 25923 E. coli ATCC 25922 
1a nt nt nt nt 
1b 9.4 (± 5.5) 4.7 (± 5.9) 6.9 (± 0.6) 4.3 (± 3.6) 
1c 0 0 61.0 (± 8.6) 0 
2c 0 0 0 3.1 (± 2.7) 
3c 0 0 0 4.9 (± 2.2) 
1d 5.5 (± 17.0) 0.3 (± 1.6) 0 5.0 (± 2.8) 
1e 11.0 (± 23.0) 0 0 5.8 (± 4.2) 
1f 1.6 (± 16.0) 3.5 (± 4.6) 0 8.1 (± 3.6) 
1g 101.0 (± 0.1) 2.1 (± 4.2) 29.0 (± 20.0) 0 
1h nt nt nt nt 
1i 24.0 (± 9.6) 6.8 (± 4.8) 0 6.2 (± 1.7) 
1j 36.7 (± 13.0) 3.3 (± 2.7) 3.4 (± 18.0) 5.9 (± 1.0) 
1k 0 0 0 7.3 (± 7.4) 
1l 1.0 (± 26.0) 0 98.0 (± 0.1) 6.5 (± 4.3) 
1m 0 0 0 0 
1n 0 0 0 3.6 (± 2.5) 
1o 101.0 (± 0.1) 0  99.0 (± 0.3) 0 
1p 4.3 (± 18.0) 0 98.0 (± 0.7) 7.8 (± 5.4) 




The general synthetic approach used included two 
alternatives: first the “Steglich esterification” using the acid of 
the selected side chain and a crown ether alcohol, utilizing 
dicyclohexylcarbodiimide as coupling agent and 4-
dimethylaminopyridine as catalytic base.10 The second approach 
consisted in the usage of the corresponding acyl chloride as 
described in the supporting information. Using this simple 
strategy we obtained the corresponding derivatives 1a-q with 
yields ranging 60-95% (Fig. 1). 
The in vitro antiproliferative activity of the crown ether acyl 
derivatives was determined in HBL-100, HeLa, SW1573 and 
WiDr human solid tumor cells. Table 1 shows the results 
(expressed as GI50) using the SRB assay.11 The standard 
anticancer drugs cisplatin (CDDP) and etoposide (VP-16) were 
used as positive controls. The most active compound of the series 
was 1p and exhibited GI50 values against all cells in the range 
3.7-5.6 µM. When compared to CDDP and VP-16, compound 1p 
showed an improved biological activity in the resistant cell line 
WiDr. In addition, the non-tumor cell line BJ-hTert (telomerase-
immortalized human foreskin fibroblasts) was used to study the 
effect on a subset of the most potent crown ether acyl derivatives 
of the series. The results show that compounds 1k and 1m are 
inactive (GI50 > 100 µM), thus indicating some selectivity, 
whilst the other derivatives showed no discrimination between 
tumor and non-tumor cell lines. Further experiments will be 
necessary to explain this outcome.  
Furthermore, the antimicrobial activity of the compounds was 
evaluated against a set of strains typically used in clinical 
antimicrobial testing by using the broth microdilution method 
according EUCAST and CLSI guidelines.12,13 All samples were 
initially tested at 50 µM. As can be seen from the primary 
screening results in Table 2, compounds 1g and 1o were highly 
active against C. albicans ATCC 90028 and compounds 1l, 1o 
and 1p displayed significant activity against Staphylococcus 
aureus ATCC 25923, fully inhibiting the growth of this Gram-
positive bacterium. Confirmatory dose-response experiments 
were carried out for these compounds.  
Compounds 1l, 1o and 1p showed MIC90 values of 25 µM, 8.3 
µM and 50 µM, respectively, against S. aureus (Table 3). Against 
C. albicans 1g and 1o exhibited MIC90 values of 36 and 42 µM, 
respectively. All the compounds were inactive against the Gram-
negative E. coli, possibly due to its outer membrane structure. 
Antimicrobial properties of crown ether derivatives have 
previously been studied by Leevy et al.4 who demonstrated that 
activity against Escherichia coli is altered by the spacer length. 
Furthermore, Gram-positive Bacillus subtilis has been 
demonstrated to be in general more susceptible to different crown 
ether derivatives than E. coli.4,14 Interestingly, the activity of 
compound 1p, the most active compound in the antiproliferative 
experiments, was about 4-fold lower against S. aureus based on 
comparison between the GI50 and MIC50 values (Table 1, Table 
3). On the other hand, compound 1o with MIC50 of 7.2 µM 
against S. aureus was only moderately active against the cancer 
cells (GI50 values in the range of 17-21 µM, Table 1). 
 
Table 3. Minimum inhibitory concentrations (MIC90, MIC50) for 
the most active compounds against S. aureus ATCC 25923 and 
C. albicans ATCC 90028. Ciprofloxacin (MIC90 against S. 
aureus 0.5 µg/mL) and amphotericin B (MIC90 against C. 
albicans 0.5 µg/mL) were used as positive controls 
         C. albicans          S. aureus 
Compound MIC90a MIC50 MIC90 MIC50 
1g 16.7 n.d.b n.d. n.d. 
1l n.d. n.d. 11.3 6.8 
1o 21.7 20.1 4.3 3.7 
1p n.d. n.d. 27.8 11.1 
a Values are given in µg/mL. 
b Not determined. 
The structure-activity relationship (SAR) study clearly 
demonstrated that the size of the crown ether and the acyl side 
chain influence the bioactivity. Initially, it was established that 
the preferred crown ether was [18]-crown-6. The selection was 
based on the GI50 values obtained for derivatives 1c, 2c and 3c in 
the antiproliferative profiling (Table 1). Then, further efforts 
were devoted to study the influence of the acyl side chain on the 
antiproliferative activity. A clear trend could not be inferred from 
the biological data. For instance, a larger aliphatic linker 
improves the antiproliferative activity of 1g when compared to 
1f. The side-chain length affects significantly the hydrophobicity 
of the compound, and thus calculated logP values for 1f and 1g 
are markedly different (1.46 and 4.63, respectively, Table 1). 
According to Supek et al.,14 logP of the molecule is the most 
important molecular descriptor in determining the biological 
activity of 18-crown-6 ethers, and not generally affected by 
features such as the side chain length or molecular symmetry. For 
our compounds, the calculated logP values vary from -0.96 to 
4.63 (Table 1). The most active compounds have logP values >3, 
but some of the moderately active or inactive compounds have 
similar values, and thus the logP does not seem to be clearly 
correlated with biological activity according to our data. Based 
on our results, improved activity was obtained when the aromatic 
structure was close to the acyl group, as exemplified with 
compounds 1l, 1p and 1q. Further experiments are necessary to 
discern if the observed differences correlate to diverse 
mechanisms of action. 
In conclusion, in this study we described an efficient strategy 
for synthesizing a series of crown ether acyl derivatives. Of the 
crown ether moieties 18-6, 15-5 and 12-4, 18-crown-6 ether core 
structure showed initially the best potential based on 
antiproliferation assays on human cancer cell lines and was thus 
chosen for synthesising a series of acyl derivatives. Compounds 
were evaluated for antiproliferative activity against HBL-100, 
HeLa, SW1573 and WiDr human solid tumor cell lines, and the 
most active compound 1p displayed GI50 values in the range of 
3.7-5.6 µM. Antimicrobial evaluation yielded compounds active 
against S. aureus and C. albicans; most active was compound 1o 
against S. aureus with MIC90 value of 8.3 µM. These results will 
be helpful in understanding the biological effects of crown ether 
derivatives, and may thus aid the development of novel 
anticancer and antimicrobial agents based on crown ether 
moieties. 
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